Lurbinectedin with osimertinib for transformed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—lurbinectedin and osimertinib—for people whose lung cancer started as EGFR-mutated non-small cell lung cancer but has changed into small cell lung cancer. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung cancer was originally EGFR-mutated non-small cell lung cancer and has now transformed into small cell lung cancer.
- You have been treated with the targeted therapy osimertinib, and the cancer progressed because of the transformation to small cell, not because of other resistance mutations like MET amplification or EGFR C797S.
- You have measurable disease (tumors that can be seen on scans).
- You are well enough to be up and about (ECOG performance status 0–2).
- Your blood counts, liver, and kidney function are adequate (checked within 21 days before starting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This trial tests whether adding lurbinectedin to paclitaxel (a standard chemo drug) helps people with small cell lung cancer that has progressed after prior treatment. You would receive either the combination or paclitaxel alone, and the study compares how well each works.
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
This trial tests a new targeted therapy (limertinib) combined with standard chemotherapy (carboplatin and etoposide) for people whose EGFR-positive lung cancer has transformed into small cell lung cancer after failing an EGFR inhibitor. The goal is to see if this combination can slow the cancer and help you live longer.
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
Hear when a new Small Cell Lung Cancer ( SCLC ) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.